Tunlametinib is a targeted therapeutic drug classified as a MEK inhibitor, primarily used to inhibit the growth and spread of cancer cells. Its core efficacy is to delay or prevent tumor progression caused by specific gene mutations (such as BRAF mutations) by blocking the MAPK signaling pathway. Common side effects include rash, diarrhea, fatigue, etc. In severe cases, it may trigger cardiac or ocular disorders. The drug must be used strictly under medical guidance, with regular physical condition monitoring.
1. Primary Efficacy
Tumor growth inhibition
It interferes with the proliferation signals of cancer cells and delays tumor progression by blocking the activity of the MEK protein.
Targeting gene mutations
It exerts favorable efficacy against solid tumors (such as melanoma and non-small cell lung cancer) harboring the BRAF V600E or V600K mutation.
Combination therapy
It is often used in combination with BRAF inhibitors (such as dabrafenib) to enhance the anti-tumor effect and reduce the risk of drug resistance.
2. Common Side Effects
Skin reactions
Rash, acne-like dermatitis, and dry skin, most of which are mild to moderate.
Gastrointestinal disorders
Diarrhea, nausea, and vomiting, which can be relieved via dietary adjustments or medication.
Systemic symptoms
Fatigue, fever, and peripheral edema (swelling of the limbs).
3. Severe Side Effects Requiring Vigilance
Cardiac toxicity
It may cause a decrease in left ventricular ejection fraction and hypertension, requiring regular electrocardiography and cardiac function tests.
Ocular disorders
Retinal vein occlusion and blurred vision; the drug must be discontinued immediately and medical attention sought if these symptoms occur.
Abnormal liver and kidney function
Elevated transaminase and serum creatinine levels, requiring regular blood tests.
4. Precautions for Use
Strictly follow medical advice
The dosage should be adjusted based on the patient’s condition and side effects; do not increase, decrease, or stop the drug without authorization.
At-risk populations
Use with caution in pregnant women, patients with severe liver and kidney insufficiency, and those with uncontrolled cardiovascular diseases.
Drug interactions
Avoid concomitant use with strong CYP3A4 inhibitors or inducers, as this may affect efficacy or increase toxicity.
Seek immediate medical attention if dyspnea, chest pain, severe diarrhea, or vision changes occur during treatment. Genetic testing should be completed before treatment to confirm the mutation status, and regular reviews of tumor markers and imaging evaluations should be performed during treatment to assess efficacy.
